State Restrictions on Mifepristone Access - The Case for Federal Preemption

N Engl J Med. 2022 Feb 24;386(8):705-707. doi: 10.1056/NEJMp2118696. Epub 2022 Jan 12.

Authors

Patricia J Zettler¹, Ameet Sarpatwari¹

Affiliation

¹ From the Moritz College of Law, the Drug Enforcement and Policy Center, and the James Comprehensive Cancer Center, Ohio State University, Columbus (P.J.Z.); and the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (A.S.).

PMID: 35020981
DOI: 10.1056/NEJMp2118696

No abstract available

MeSH terms

Abortifacient Agents, Steroidal*
Abortion, Legal / legislation & jurisprudence*
Civil Rights / legislation & jurisprudence
Federal Government*
Female
Government Regulation
Humans
Legislation, Drug*
Mifepristone*
Pregnancy
Public Health / legislation & jurisprudence
Reproductive Rights / legislation & jurisprudence*
State Government*
United States
United States Food and Drug Administration

Substances

Abortifacient Agents, Steroidal
Mifepristone